Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
FDA issues 30 warning letters to telehealth firms for falsely claiming compounded GLP-1 drugs are equivalent to approved versions.
The FDA issued 30 warning letters to telehealth companies for falsely claiming compounded GLP-1 drugs are equivalent to FDA-approved versions, stressing these unapproved products lack rigorous safety and quality reviews.
The agency is cracking down on misleading direct-to-consumer ads, targeting companies that promote compounded drugs under brand names without disclosing the actual compounder.
This follows broader actions including over 40 warning letters and 100 cease-and-desist notices, with intensified scrutiny on foreign-sourced active ingredients and import restrictions.
The move aims to protect public health amid rising concerns over unregulated compounding practices.
La FDA emite 30 cartas de advertencia a las empresas de telemedicina por afirmar falsamente que los medicamentos compuestos GLP-1 son equivalentes a las versiones aprobadas.